Literature DB >> 2312445

Clinical experiences with fusidic acid in cystic fibrosis patients.

T Jensen1, S Lanng, M Faber, V T Rosdahl, N Høiby, C Koch.   

Abstract

A survey of Staphylococcus aureus lung infection in 243 patients with cystic fibrosis (CF) was conducted between 1986 and 1988. A total of 217 patients (89%) received 1605 courses of anti-staphylococcal therapy given during this period. The majority of courses comprised combined therapy with two anti-staphylococcal drugs. The combination of dicloxacillin and fusidic acid was employed most frequently. Some patients were given other anti-staphylococcal regimens, because of penicillin allergy (14 cases) or dyspeptic side effects with fusidic acid (21 patients). A small but significant increase in precipitins against S. aureus was observed during the study period. Bacterial resistance to the anti-staphylococcal drugs used remained at a low level (strains resistant to methicillin less than 0.1%, strains resistant to fusidic acid 1.2%). When the isolates were compared with 56,140 strains of S. aureus isolated from non-CF patients hospitalized in Denmark over the same period, no differences in phagetypes or in antibiotic resistance were seen, indicating that selection of strains and cross infection do not seem to be a major problem in CF patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2312445     DOI: 10.1093/jac/25.suppl_b.45

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Activity of antimicrobial peptides, alone or combined with conventional antibiotics, against Staphylococcus aureus isolated from the airways of cystic fibrosis patients.

Authors:  Katarzyna Garbacz; Wojciech Kamysz; Lidia Piechowicz
Journal:  Virulence       Date:  2016-07-22       Impact factor: 5.882

2.  In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  Pamela McGhee; Catherine Clark; Kim Credito; Linda Beachel; Glenn A Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 3.  Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis.

Authors:  K McCaffery; R E Olver; M Franklin; S Mukhopadhyay
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

4.  Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.

Authors:  Margaret Rosenfeld; Oli Rayner; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2020-09-30

Review 5.  Treatment of pseudomonas and Staphylococcus bronchopulmonary infection in patients with cystic fibrosis.

Authors:  Rashmi Ranjan Das; Sushil Kumar Kabra; Meenu Singh
Journal:  ScientificWorldJournal       Date:  2013-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.